Somatic cell type specific gene transfer reveals a tumor-promoting function for p21Waf1/Cip1

EMBO Journal

Volumn 26, Issue 22, 2007, Pages 4683-4693

  Liu, Yuhui ^a   Yeh, Nancy ^a   Zhu, Xin Hua ^a   Leversha, Margaret ^a   Cordon Cardo, Carlos ^a   Ghossein, Ronald ^a   Singh, Bhuvanesh ^a   Holland, Eric ^a   Koff, Andrew ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

cdk inhibitor; Cyclin D; Glioma; Oligodendrocyte

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; PROTEIN P21;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOACCUMULATION; CARCINOGENESIS; CELL NUCLEUS; CELL TYPE; COMPLEX FORMATION; CONTROLLED STUDY; EMBRYO; GENE TRANSFER; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; SOMATIC CELL; TUMOR GROWTH;

ANIMALS; AVIAN PROTEINS; CELL LINE; CHICKENS; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; MICE; MICE, TRANSGENIC; OLIGODENDROGLIOMA; PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VIRUS; RETROVIRIDAE;

MUS;

EID: 36249013223     PISSN: 02614189     EISSN: 14602075     Source Type: Journal    
DOI: 10.1038/sj.emboj.7601886     Document Type: Article

References (77)

1. Aaltomaa S, Lipponen P, Eskelinen M, Ala-Opas M, Kosma VM (1999) Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer. Prostate 39: 8-15
2. Alt JR, Cleveland JL, Hannink M, Diehl JA (2000) Phosphorylation- dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 14: 3102-3114
3. Alt JR, Gladden AB, Diehl JA (2002) p21(Cip1) promotes cyclin D1 nuclear accumulation via direct inhibition of nuclear export. J Biol Chem 277: 8517-8523
4. Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, Mizutani S (1999) Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J 18: 1223-1234
5. Bae DS, Cho SB, Kim YJ, Whang JD, Song SY, Park CS, Kim DS, Lee JH (2001) Aberrant expression of cyclin D1 is associated with poor prognosis in early stage cervical cancer of the uterus. Gynecol Oncol 81: 341-347
6. Bannykh SI, Stolt CC, Kim J, Perry A, Wegner M (2006) Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas. J Neurooncol 76: 115-127
7. Baretton GB, Klenk U, Diebold J, Schmeller N, Lohrs U (1999) Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br J Cancer 80: 546-555
8. Besson A, Gurian-West M, Schmidt A, Hall A, Roberts JM (2004) p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev 18: 862-876
9. Besson A, Hwang HC, Cicero S, Donovan SL, Gurian-West M, Johnson D, Clurman BE, Dyer MA, Roberts JM (2007) Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev 21: 1731-1746
10. Betsholtz C (2004) Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev 15: 215-228
11. Blagosklonny MV (2002) Are p27 and p21 cytoplasmic oncoproteins? Cell Cycle 1: 391-393
12. Blain SW, Montalvo E, Massague J (1997) Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4. J Biol Chem 272: 25863-25872
13. Casaccia-Bonnefil P, Hardy RJ, Teng KK, Levine JM, Koff A, Chao MV (1999) Loss of p27Kip1 function results in increased proliferative capacity of oligodendrocyte progenitors but unaltered timing of differentiation. Development 126: 4027-4037
14. Casaccia-Bonnefil P, Tikoo R, Kiyokawa H, Friedrich Jr V, Chao MV, Koff A (1997) Oligodendrocyte precursor differentiation is perturbed in the absence of the cyclin-dependent kinase inhibitor p27Kip1. Genes Dev 11: 2335-2346
15. Cavalla P, Piva R, Bortolotto S, Grosso R, Cancelli I, Chio A, Schiffer D (1999) p27/kip1 expression in oligodendrogliomas and its possible prognostic role. Acta Neuropathol (Berl) 98: 629-634
16. Ceccarelli C, Santini D, Chieco P, Lanciotti C, Taffurelli M, Paladini G, Marrano D (2001) Quantitative p21(waf-1)/p53 immunohistochemical analysis defines groups of primary invasive breast carcinomas with different prognostic indicators. Int J Cancer 95: 128-134
17. Chen J, Saha P, Kornbluth S, Dynlacht BD, Dutta A (1996) Cyclin-binding motifs are essential for the function of p21CIP1. Mol Cell Biol 16: 4673-4682
18. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr CJ (1999) The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 18: 1571-1583
19. Cheung TH, Lo KW, Yu MM, Yim SF, Poon CS, Chung TK, Wong YF (2001) Aberrant expression of p21(WAF1/CIP1) and p27(KIP1) in cervical carcinoma. Cancer Lett 172: 93-98
20. Child ES, Mann DJ (2006) The intricacies of p21 phosphorylation: protein/protein interactions, subcellular localization and stability. Cell Cycle 5: 1313-1319
21. Collins VP (2004) Brain tumours: classification and genes. J Neurol Neurosurg Psychiatry 75 (Suppl 2): ii2-ii11
22. Coqueret O (2003) New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 13: 65-70
23. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC (2001) PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 15: 1913-1925
24. Denicourt C, Dowdy SF (2004) Cip/Kip proteins: more than just CDKs inhibitors. Genes Dev 18: 851-855
25. Diehl JA, Sherr CJ (1997) A dominant-negative cyclin D1 mutant prevents nuclear import of cyclin-dependent kinase 4 (CDK4) and its phosphorylation by CDK-activating kinase. Mol Cell Biol 17: 7362-7374
26. Doetsch F, Garcia-Verdugo JM, Alvarez-Buylla A (1997) Cellular composition and three-dimensional organization of the subventricular germinal zone in the adult mammalian brain. J Neurosci 17: 5046-5061
27. Doetsch F, Verdugo JM, Caille I, Alvarez-Buylla A, Chao MV, Casaccia-Bonnefil P (2002) Lack of the cell-cycle inhibitor p27Kip1 results in selective increase of transit-amplifying cells for adult neurogenesis. J Neurosci 22: 2255-2264
28. Dotto GP (2000) p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta 1471: M43-M56
29. Fisher GH, Orsulic S, Holland E, Hively WP, Li Y, Lewis BC, Williams BO, Varmus HE (1999) Development of a flexible and specific gene delivery system for production of murine tumor models. Oncogene 18: 5253-5260
30. Gao H, Ouyang X, Banach-Petrosky W, Borowsky AD, Lin Y, Kim M, Lee H, Shih WJ, Cardiff RD, Shen MM, Abate-Shen C (2004) A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA 101: 17204-17209
31. Gartel AL (2005) The conflicting roles of the cdk inhibitor p21(CIP1/ WAF1) in apoptosis. Leuk Res 29: 1237-1238
32. Gartel AL (2006a) Inducer and inhibitor: 'antagonistic duality' of p21 in differentiation. Leuk Res 30: 1215-1216
33. Gartel AL (2006b) Is p21 an oncogene? Mol Cancer Ther 5: 1385-1386
34. Gartel AL, Tyner AL (2002) The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1: 639-649
35. Gladden AB, Woolery R, Aggarwal P, Wasik MA, Diehl JA (2006) Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene 25: 998-1007
36. Glaser T, Wagenknecht B, Weller M (2001) Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells. Oncogene 20: 4757-4767
37. Guha A, Dashner K, Black PM, Wagner JA, Stiles CD (1995a) Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer 60: 168-173
38. Guha A, Glowacka D, Carroll R, Dashner K, Black PM, Stiles CD (1995b) Expression of platelet derived growth factor and platelet derived growth factor receptor mRNA in a glioblastoma from a patient with Li-Fraumeni syndrome. J Neurol Neurosurg Psychiatry 58: 711-714
39. Hinds PW, Dowdy SF, Eaton EN, Arnold A, Weinberg RA (1994) Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA 91: 709-713
40. Holland EC (2001a) Animal models of cell cycle dysregulation and the pathogenesis of gliomas. J Neurooncol 51: 265-276
41. Holland EC (2001b) Brain tumor animal models: importance and progress. Curr Opin Oncol 13: 143-147
42. Holland EC (2001c) Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2: 120-129
43. Jin K, Mao XO, Batteur S, Sun Y, Greenberg DA (2003) Induction of neuronal markers in bone marrow cells: differential effects of growth factors and patterns of intracellular expression. Exp Neurol 184: 78-89
44. Jones JM, Cui XS, Medina D, Donehower LA (1999) Heterozygosity of p21WAF1/CIP1 enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model. Cell Growth Differ 10: 213-222
45. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E (1997) New functional activities for the p21 family of CDK inhibitors. Genes Dev 11: 847-862
46. Lin DI, Barbash O, Kumar KG, Weber JD, Harper JW, Klein-Szanto AJ, Rustgi A, Fuchs SY, Diehl JA (2006) Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex. Mol Cell 24: 355-366
47. Liu Y, Encinas M, Comella JX, Aldea M, Gallego C (2004) Basic helix-loop-helix proteins bind to TrkB and p21(Cip1) promoters linking differentiation and cell cycle arrest in neuroblastoma cells. Mol Cell Biol 24: 2662-2672
48. Liu Y, Wu Y, Lee JC, Xue H, Pevny LH, Kaprielian Z, Rao MS (2002) Oligodendrocyte and astrocyte development in rodents: an in situ and immunohistological analysis during embryonic development. Glia 40: 25-43
49. Louis DN, Holland EC, Cairncross JG (2001) Glioma classification: a molecular reappraisal. Am J Pathol 159: 779-786
50. Louis DN, Pomeroy SL, Cairncross JG (2002) Focus on central nervous system neoplasia. Cancer Cell 1: 125-128
51. McAllister SS, Becker-Hapak M, Pintucci G, Pagano M, Dowdy SF (2003) Novel p27(kip1) C-terminal scatter domain mediates Rac-dependent cell migration independent of cell cycle arrest functions. Mol Cell Biol 23: 216-228
52. Miettinen HE, Paunu N, Rantala I, Kalimo H, Paljarvi L, Helin H, Haapasalo H (2001) Cell cycle regulators (p21, p53, pRb) in oligodendrocytic tumors: a study by novel tumor microarray technique. J Neurooncol 55: 29-37
53. Moeller SJ, Head ED, Sheaff RJ (2003) p27Kip1 inhibition of GRB2-SOS formation can regulate Ras activation. Mol Cell Biol 23: 3735-3752
54. Muraoka RS, Lenferink AE, Law B, Hamilton E, Brantley DM, Roebuck LR, Arteaga CL (2002) ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Mol Cell Biol 22: 2204-2219
55. Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ, DiRenzo J, Pestell RG, Hinds PW, Dowdy SF, Brown M, Ewen ME (1997) Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 17: 5338-5347
56. Nguyen L, Besson A, Heng JI, Schuurmans C, Teboul L, Parras C, Philpott A, Roberts JM, Guillemot F (2006) p27kip1 independently promotes neuronal differentiation and migration in the cerebral cortex. Genes Dev 20: 1511-1524
57. Omar EA, Behlouli H, Chevalier S, Aprikian AG (2001) Relationship of p21(WAF-I) protein expression with prognosis in advanced prostate cancer treated by androgen ablation. Prostate 49: 191-199
58. Perkins ND (2002) Not just a CDK inhibitor: regulation of transcription by p21(WAF1/CIP1/SDI1). Cell Cycle 1: 39-41
59. Reutens AT, Fu M, Wang C, Albanese C, McPhaul MJ, Sun Z, Balk SP, Janne OA, Palvimo JJ, Pestell RG (2001) Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol Endocrinol 15: 797-811
60. Rost B, Yachdav G, Liu J (2004) The PredictProtein server. Nucleic Acids Res 32: W321-W326
61. Salpietro M, Holland EC (2005) Modeling and preclinical trials for gliomas. Clin Neurosurg 52: 104-111
62. Sarbia M, Stahl M, zur Hausen A, Zimmermann K, Wang L, Fink U, Heep H, Dutkowski P, Willers R, Muller W, Seeber S, Gabbert HE (1998) Expression of p21WAF1 predicts outcome of esophageal cancer patients treated by surgery alone or by combined therapy modalities. Clin Cancer Res 4: 2615-2623
63. Shaffer DR, Viale A, Ishiwata R, Leversha M, Olgac S, Manova K, Satagopan J, Scher H, Koff A (2005) Evidence for a p27 tumor suppressive function independent of its role regulating cell proliferation in the prostate. Proc Natl Acad Sci USA 102: 210-215
64. Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512
65. Shih AH, Dai C, Hu X, Rosenblum MK, Koutcher JA, Holland EC (2004) Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res 64: 4783-4789
66. Soos TJ, Kiyokawa H, Yan JS, Rubin MS, Giordano A, DeBlasio A, Bottega S, Wong B, Mendelsohn J, Koff A (1996) Formation of p27-CDK complexes during the human mitotic cell cycle. Cell Growth Differ 7: 135-146
67. Suzuki A, Ito T, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y, Akahane K, Nakano T, Miura M, Shiraki K (2000a) Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene 19: 1346-1353
68. Suzuki A, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y, Akahane K (2000b) Procaspase 3/p21 complex formation to resist fas-mediated cell death is initiated as a result of the phosphorylation of p21 by protein kinase A. Cell Death Differ 7: 721-728
69. Suzuki A, Tsutomi Y, Akahane K, Araki T, Miura M (1998) Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene 17: 931-939
70. Suzuki A, Tsutomi Y, Miura M, Akahane K (1999) Caspase 3 inactivation to suppress Fas-mediated apoptosis: identification of binding domain with p21 and ILP and inactivation machinery by p21. Oncogene 18: 1239-1244
71. Weiss RH (2003) p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 4: 425-429
72. Weiss RH, Joo A, Randour C (2000) p21(Waf1/Cip1) is an assembly factor required for platelet-derived growth factor-induced vascular smooth muscle cell proliferation. J Biol Chem 275: 10285-10290
73. Wu FY, Wang SE, Sanders ME, Shin I, Rojo F, Baselga J, Arteaga CL (2006) Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity. Cancer Res 66: 2162-2172
74. Yu Q, Geng Y, Sicinski P (2001) Specific protection against breast cancers by cyclin D1 ablation. Nature 411: 1017-1021
75. Zezula J, Casaccia-Bonnefil P, Ezhevsky SA, Osterhout DJ, Levine JM, Dowdy SF, Chao MV, Koff A (2001) p21cip1 is required for the differentiation of oligodendrocytes independently of cell cycle withdrawal. EMBO Rep 2: 27-34
76. Zhan J, Easton JB, Huang S, Mishra A, Xiao L, Lacy ER, Kriwacki RW, Houghton PJ (2007) Negative regulation of ASK1 by p21Cip1 involves a small domain that includes serine 98 that is phosphorylated by ASK1 in vivo. Mol Cell Biol 27: 3530-3541
77. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJ (1997) CDK-independent activation of estrogen receptor by cyclin D1. Cell 88: 405-415